CPA
EPZM

Cowen Prime Advisors’s Epizyme, Inc EPZM Stock Holding History

Cowen Prime Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,950
Closed -$93K – 314
2015
Q1 		$93K Buy
4,950
+2,300
+87% +$47.5K 0.04% 153
2014
Q4 		$50K Buy
2,650
+250
+10% +$5.84K 0.02% 194
2014
Q3 		$65K Sell
2,400
-700
-23% -$21.8K 0.03% 169
2014
Q2 		$96K Buy
3,100
+150
+5% +$3.53K 0.04% 141
2014
Q1 		$67K Buy
+2,950
New +$89.4K 0.03% 160

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Cowen Prime Advisors's EPZM Position: Q2 2015 in Review

Cowen Prime Advisors sold out of Epizyme, Inc (EPZM) in Q2 2015, closing a stake of 4,950 shares — an estimated $93K sold.

Cowen Prime Advisors first reported a position in EPZM in Q1 2014 and held it in 5 quarters. The position peaked at $96K in Q2 2014. 95 funds tracked by Wall St. Rank hold EPZM as of Q2 2015.

  • Cowen Prime Advisors reported no remaining Epizyme, Inc position as of Q2 2015 after selling out during the quarter.
  • Cowen Prime Advisors sold 4,950 Epizyme, Inc shares in Q2 2015, an estimated $93K.
  • Cowen Prime Advisors first reported a position in Epizyme, Inc in Q1 2014 and held it in 5 quarters.
  • Cowen Prime Advisors's Epizyme, Inc position peaked at $96K in Q2 2014.
  • 95 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2015.

Based on Cowen Prime Advisors's 13F filing for Q2 2015, filed 10 Aug 2015.